Associated tags: Ras GTPase, RAS, SHP2, Pharmaceutical industry, Revolution, Patient, Conference, Cancer
Locations: RAS, NEW YORK, BOSTON, ASIA, CHINA, PK, NEEDHAM, REDWOOD CITY, CA, US, KRAS, EUROPE, CALIFORNIA
Mutation,
Safety,
Pembrolizumab,
Research,
Asian literature,
CRC,
RAS,
SHP2,
Initiation,
Trial of the century,
Disclosure,
PDAC,
BRAF,
Patient,
SOC,
Neoplasm,
NRAS,
AACR,
Clinical trial,
Sanofi,
G13,
GAAP,
Lung cancer,
Pharmaceutical industry REDWOOD CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial results for the quarter ended March 31, 2024, and provided an update on corporate progress.
Key Points:
- REDWOOD CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced its financial results for the quarter ended March 31, 2024, and provided an update on corporate progress.
- The company continues making progress on its 2024 development priorities:
Advancing its RAS(ON) multi-selective inhibitor RMC-6236 into monotherapy pivotal trials.
- Revenue: Total revenue was zero for the quarter ended March 31, 2024, compared to $7.0 million for the quarter ended March 31, 2023.
- Revolution Medicines will host a webcast this afternoon, May 8, 2024, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).
Mutation,
Growth,
NSCLC,
Colorectal cancer,
RAS,
Patient,
Research,
PDAC,
Lung cancer,
GTP,
AACR,
Clinical trial,
Cancer,
CRC,
G13,
G12,
Pharmaceutical industry This original research was led by scientists at Revolution Medicines and conducted in collaboration with researchers from across the U.S. and Europe.
Key Points:
- This original research was led by scientists at Revolution Medicines and conducted in collaboration with researchers from across the U.S. and Europe.
- Oncogenic RAS proteins drive up to 30 percent of all human cancers, most notably non-small cell lung cancer (NSCLC), colorectal cancer (CRC) and pancreatic ductal adenocarcinoma (PDAC).
- RAS G12 mutations, such as G12D, G12V and G12C, predominate in human cancers.
- The paper describes the discovery of RMC-6236, an oral, multi-selective inhibitor of the active GTP-bound (ON) state of both mutant and wild-type RAS.
NSCLC,
Colorectal cancer,
CYPA,
RAS,
Patient,
Research,
PDAC,
Lung cancer,
Protein,
Trial of the century,
GTP,
Cancer,
CRC,
Pharmacology,
Ras GTPase,
Drug resistance,
Pharmaceutical industry REDWOOD CITY, Calif., April 08, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the publication of two peer-reviewed research papers in Nature. The first paper highlights the discovery and preclinical characterization of RMC-7977, a preclinical tool compound representative of a class of oral RAS(ON) multi-selective inhibitors, including the investigational drug candidate RMC-6236, that target multiple RAS variants. The second paper highlights the systematic evaluation of RMC-7977 in a wide range of preclinical models of PDAC. This original research was led by scientists at Revolution Medicines and conducted in collaboration with researchers from across the U.S. and Europe.
Key Points:
- The first paper highlights the discovery and preclinical characterization of RMC-7977, a preclinical tool compound representative of a class of oral RAS(ON) multi-selective inhibitors, including the investigational drug candidate RMC-6236, that target multiple RAS variants.
- The second paper highlights the systematic evaluation of RMC-7977 in a wide range of preclinical models of PDAC.
- This original research was led by scientists at Revolution Medicines and conducted in collaboration with researchers from across the U.S. and Europe.
- Oncogenic RAS proteins drive up to 30 percent of all human cancers, most notably non-small cell lung cancer (NSCLC), PDAC and colorectal cancer (CRC).
REDWOOD CITY, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will be a featured speaker at the 23rd Annual Needham Healthcare Conference and the Stifel Targeted Oncology Forum.
Key Points:
- REDWOOD CITY, Calif., April 04, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will be a featured speaker at the 23rd Annual Needham Healthcare Conference and the Stifel Targeted Oncology Forum.
- Details of the company’s participation are as follows:
To access the live webcasts of the Needham and Stifel fireside chats, please visit the “Events & Presentations” page of Revolution Medicines’ website at https://ir.revmed.com/events-and-presentations .
- Additionally, a replay of each webcast will be available on the “Events & Presentations” page of the Revolution Medicines website for at least 14 days following the conference.
REDWOOD CITY, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the company will deliver multiple presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024 being held April 5-10, 2024, in San Diego, California.
Key Points:
- REDWOOD CITY, Calif., March 28, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced the company will deliver multiple presentations at the upcoming American Association for Cancer Research (AACR) Annual Meeting 2024 being held April 5-10, 2024, in San Diego, California.
- Details of the planned presentations are listed below:
Retrieved on:
Monday, February 26, 2024
NSCLC,
Acquisition,
Research,
Neoplasm,
Investment,
Melanoma,
Conference,
RAS,
Lung cancer,
Safety,
Sanofi,
GAAP,
PDAC,
Patient,
Acceleration,
Clinical trial,
Congress,
Trial of the century,
Colorectal cancer,
Pharmaceutical industry “2023 was a transformative year for Revolution Medicines and our pioneering RAS(ON) inhibitors.
Key Points:
- “2023 was a transformative year for Revolution Medicines and our pioneering RAS(ON) inhibitors.
- Revenue: Total revenue was $0.7 million for the quarter ended December 31, 2023, compared to $15.3 million for the quarter ended December 31, 2022.
- Net loss for the year ended December 31, 2023, included $26.9 million of operating expenses related to the wind-down of EQRx.
- Revolution Medicines will host a webcast this afternoon, February 26, 2024, at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time).
Retrieved on:
Tuesday, February 20, 2024
REDWOOD CITY, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the fourth quarter and full year 2023 on Monday, February 26, 2024, after market close.
Key Points:
- REDWOOD CITY, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers, today announced that it will report financial results for the fourth quarter and full year 2023 on Monday, February 26, 2024, after market close.
- At 4:30 p.m. Eastern Time that day (1:30 p.m. Pacific Time), Revolution Medicines’ senior management team will host a webcast to discuss the financial results for the quarter and full year, and provide an update on corporate progress.
- To listen to the live webcast, or access the archived webcast, please visit: https://ir.revmed.com/events-and-presentations .
- Following the live webcast, a replay will be available on the company’s website for at least 14 days.
Retrieved on:
Thursday, February 1, 2024
REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will be a featured speaker at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference and the TD Cowen 44th Annual Health Care Conference.
Key Points:
- REDWOOD CITY, Calif., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will be a featured speaker at the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference and the TD Cowen 44th Annual Health Care Conference.
- Details of the company’s participation are as follows:
To access the live webcasts of the presentations, please visit the “Events & Presentations” page of Revolution Medicines’ website at https://ir.revmed.com/events-and-presentations .
- Additionally, replays of the webcasts will be available on the “Events & Presentations” page of the Revolution Medicines website for at least 14 days following each conference.
Retrieved on:
Thursday, January 4, 2024
REDWOOD CITY, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will deliver a corporate presentation as part of the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 11:15 a.m. PT.
Key Points:
- REDWOOD CITY, Calif., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced that Mark A. Goldsmith, M.D., Ph.D., the company’s chief executive officer and chairman, will deliver a corporate presentation as part of the 42nd Annual J.P. Morgan Healthcare Conference on Tuesday, January 9, 2024, at 11:15 a.m. PT.
- To access the live webcast of the presentation, please visit the “Events & Presentations” page of Revolution Medicines’ website at https://ir.revmed.com/events-and-presentations .
- Additionally, a replay of the webcast will be available on the “Events & Presentations” page of the Revolution Medicines website for at least 14 days following the conference.
Retrieved on:
Thursday, November 9, 2023
Standard of care,
RAS,
Public Sector Net Cash Requirement,
Stanford University,
Health care,
Guggenheim Partners,
Moores Cancer Center,
Duane J. Roth,
Acquisition,
University of Iowa School of Music,
Moderna,
Revolution,
Medicine,
Latham & Watkins,
University,
Genentech,
Cancer,
Investment,
Patient,
Goldman Sachs,
Pharmaceutical industry REDWOOD CITY, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced it has closed its acquisition of EQRx, Inc.
Key Points:
- Acquisition Expected to Add Approximately $1.1 Billion in Net Cash to Revolution Medicines’ Balance Sheet, Supporting Late-Stage Development of RAS(ON) Inhibitor Investigational Drugs
REDWOOD CITY, Calif., Nov. 09, 2023 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a clinical-stage oncology company developing targeted therapies for RAS-addicted cancers, today announced it has closed its acquisition of EQRx, Inc.
- Through the acquisition, Revolution Medicines expects to add approximately $1.1 billion in net cash proceeds to its balance sheet, after estimated post-closing EQRx wind-down and transition costs.
- Each share of common stock of EQRx issued has been converted into the right to receive 0.1112 shares of common stock of Revolution Medicines.
- EQRx common stock has ceased trading on the Nasdaq Global Market and all EQRx programs are being wound down.
